VTAMA® (tapinarof) cream, 1%

SIGNIFICANTLY CLEARER SKIN

VTAMA cream is the only aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of plaque psoriasis in adults

See the Science

SIGNIFICANTLY CLEARER SKIN

In the 12-week pivotal studies, up to 40% of adult patients with plaque psoriasis achieved PGA treatment success on VTAMA vs 6% on vehicle^1,2,*

First in Class

VTAMA is the first and only AhR agonist indicated for the topical treatment of plaque psoriasis in adults.

Discover the Science

Proven Results

Across all disease severities, skin tones, and treatment areas. In the 12-week pivotal studies, up to 40% of adult patients with plaque psoriasis achieved PGA treatment success on VTAMA vs 6% on vehicle.^3,*

Explore the Efficacy

Consecutive Treatment-Free Months

Clinically proven to deliver sustained results, even during treatment-free months.

Following 12 weeks of treatment with VTAMA, plaque psoriasis patients (n=73) entered the open-label, long-term extension (LTE) study with clear skin (PGA=0) and had VTAMA withdrawn. These patients were followed for up to 40 additional weeks with a median duration of disease control (PGA=0 or 1) of 114 consecutive days (~4 months) off therapy for the ﬁrst treatment-free interval.⁴

Analyze Results

Dual-Indication
Steroid-Free Topical
No-to-Minimal Systemic Absorption⁵

*In PSOARING 1 and PSOARING 2, PGA success, defined as PGA=0 or 1 and ≥2-grade improvement from baseline at Week 12, was achieved by 36% and 40% of patients on VTAMA vs 6% (P<0.0001) and 6% (P<0.0001) of patients on vehicle, respectively.

Visible Results

Age: 28
Gender: Male
Primary Endpoint Success^6,†

Baseline

Physician Rated

PGA=4

Patient Rated

DLQI=16
PP-NRS=6

Week 8

Physician Rated

PGA=2

Patient Rated

DLQI=N/A
PP-NRS=0

Week 12

Physician Rated

PGA=1

Patient Rated

DLQI=1
PP-NRS=0

Review Clinical Images

Please note that the scores reflect a global assessment of the patient’s plaque psoriasis, whereas the images are only representative of one lesion or body area. Individual results may vary.

DLQI, Dermatology Life Quality Index; LTE, long-term extension; PGA, Physician Global Assessment; PP-NRS, Peak Pruritus-Numeric Rating Scale.
^†Primary endpoint success refers to the primary study endpoint of a patient achieving a PGA score of 0 or 1 and ≥2-grade improvement from baseline at week 12.

Strictly Necessary Cookies	Always active
Performance Cookies
Targeting Cookies

SIGNIFICANTLY CLEARER SKIN

SIGNIFICANTLY CLEARER SKIN

In the 12-week pivotal studies, up to 40% of adult patients with plaque psoriasis achieved PGA treatment success on VTAMA vs 6% on vehicle1,2,*

First in Class

Proven Results

Consecutive Treatment-Free Months

Visible Results

1. How likely are you to let the American Academy of Dermatology (AAD) guidelines influence your treatment decisions?

2. How likely are you to consider a branded topical treatment over a generic topical option?

3. What level of experience do you have with VTAMA cream?

Manage Consent Preferences

In the 12-week pivotal studies, up to 40% of adult patients with plaque psoriasis achieved PGA treatment success on VTAMA vs 6% on vehicle^1,2,*